Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023786183> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2023786183 abstract "You have accessJournal of UrologyPenis/Testis/Urethra: Benign & Malignant Disease1 Apr 2011588 OUTCOMES OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOLLOWING HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT Kelly Cary, Stephen Beck, Richard Bihrle, and Richard Foster Kelly CaryKelly Cary Indianapolis, IN More articles by this author , Stephen BeckStephen Beck Indianapolis, IN More articles by this author , Richard BihrleRichard Bihrle Indianapolis, IN More articles by this author , and Richard FosterRichard Foster Indianapolis, IN More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.1420AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To determine pathologic findings and survival in patients receiving high-dose chemotherapy (HDCT) with stem cell transplant who under go post-chemotherapy retroperitoneal lymph node dissection (PCRPLND). METHODS The testis cancer database was retrospectively reviewed to identify patients undergoing PCRPLND after receiving HDCT. 80 patients were identified. 3 patients were excluded due to incomplete follow-up data. RESULTS Risk classification at initial presentation for the 77 patients was good, intermediate and poor in 29 (38%), 17 (22%), and 31 (40%), respectively. No patient received HDCT as first line therapy. For the entire group, pathology revealed necrosis in 21 (27.3%), teratoma in 26 (33.8%) and active cancer in 30 (39%). For the 65 patients receiving HDCT as second line treatment, pathology was necrosis in 28%, teratoma in 38%, and active cancer in 34% compared to 25% necrosis, 8% teratoma, and 67% active cancer in the 12 patients receiving HDCT as third line treatment (p=0.06). At a median follow up of 50 months the overall survival (OS) for the 77 patients was 70.1%. The 2-year OS was 69.6%, 92.3%, 50.3% for necrosis, teratoma and active cancer, respectively (p=0.002). The overall survival for patients receiving HDCT as second line versus third line therapy was 73% versus 57% (p=0.243). CONCLUSIONS In patients who require PC RPLND after HDCT the incidence of germ cell cancer in the specimen is 39%. HDCT given as second line therapy appears to improve both pathologic and clinical outcomes as compared to when given as third line therapy. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e237 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kelly Cary Indianapolis, IN More articles by this author Stephen Beck Indianapolis, IN More articles by this author Richard Bihrle Indianapolis, IN More articles by this author Richard Foster Indianapolis, IN More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
- W2023786183 created "2016-06-24" @default.
- W2023786183 creator A5016474171 @default.
- W2023786183 creator A5035913183 @default.
- W2023786183 creator A5078996026 @default.
- W2023786183 creator A5082433999 @default.
- W2023786183 date "2011-04-01" @default.
- W2023786183 modified "2023-09-24" @default.
- W2023786183 title "588 OUTCOMES OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOLLOWING HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT" @default.
- W2023786183 doi "https://doi.org/10.1016/j.juro.2011.02.1420" @default.
- W2023786183 hasPublicationYear "2011" @default.
- W2023786183 type Work @default.
- W2023786183 sameAs 2023786183 @default.
- W2023786183 citedByCount "0" @default.
- W2023786183 crossrefType "journal-article" @default.
- W2023786183 hasAuthorship W2023786183A5016474171 @default.
- W2023786183 hasAuthorship W2023786183A5035913183 @default.
- W2023786183 hasAuthorship W2023786183A5078996026 @default.
- W2023786183 hasAuthorship W2023786183A5082433999 @default.
- W2023786183 hasConcept C126322002 @default.
- W2023786183 hasConcept C141071460 @default.
- W2023786183 hasConcept C2775862295 @default.
- W2023786183 hasConcept C2776057878 @default.
- W2023786183 hasConcept C2776212926 @default.
- W2023786183 hasConcept C2776694085 @default.
- W2023786183 hasConcept C2779511695 @default.
- W2023786183 hasConcept C2780849966 @default.
- W2023786183 hasConcept C71924100 @default.
- W2023786183 hasConceptScore W2023786183C126322002 @default.
- W2023786183 hasConceptScore W2023786183C141071460 @default.
- W2023786183 hasConceptScore W2023786183C2775862295 @default.
- W2023786183 hasConceptScore W2023786183C2776057878 @default.
- W2023786183 hasConceptScore W2023786183C2776212926 @default.
- W2023786183 hasConceptScore W2023786183C2776694085 @default.
- W2023786183 hasConceptScore W2023786183C2779511695 @default.
- W2023786183 hasConceptScore W2023786183C2780849966 @default.
- W2023786183 hasConceptScore W2023786183C71924100 @default.
- W2023786183 hasIssue "4S" @default.
- W2023786183 hasLocation W20237861831 @default.
- W2023786183 hasOpenAccess W2023786183 @default.
- W2023786183 hasPrimaryLocation W20237861831 @default.
- W2023786183 hasRelatedWork W1978705140 @default.
- W2023786183 hasRelatedWork W2060631358 @default.
- W2023786183 hasRelatedWork W2158826408 @default.
- W2023786183 hasRelatedWork W2212630809 @default.
- W2023786183 hasRelatedWork W2401215387 @default.
- W2023786183 hasRelatedWork W2409926368 @default.
- W2023786183 hasRelatedWork W2412192487 @default.
- W2023786183 hasRelatedWork W2575446955 @default.
- W2023786183 hasRelatedWork W3015176815 @default.
- W2023786183 hasRelatedWork W4231174420 @default.
- W2023786183 hasVolume "185" @default.
- W2023786183 isParatext "false" @default.
- W2023786183 isRetracted "false" @default.
- W2023786183 magId "2023786183" @default.
- W2023786183 workType "article" @default.